Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.
US-based contract development and manufacturing organization (CDMO) Patheon has registered with the SEC as part of plans to go public with an IPO that could be worth as much as $100m.
Patheon is the world’s largest pharmaceutical development services (PDS) provider and third largest contract manufacturer, according to a report released yesterday.
Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting shares before April 27 2012.
Patheon has posted “disappointing” Q3 results, with manufacturing difficulties in Puerto Rico, a slowdown in demand for development services and reduced client demand for some products impacting on revenues.
Patheon chief Wes Wheeler says the drop in Q1 losses the firm recently reported is due to the “restructuring activities and rigorous cost containment efforts” it enacted towards the end of last year.
There is still no formal offer on the table for Canadian contract manufacturer Patheon from JLL Patheon Holdings, an investment group which currently owns around 29 per cent of the firm.
Contract development and manufacturing company Patheon received an unsolicited takeover bid from private equity firm JLL Partners ahead of reporting a return to profit in its fiscal fourth quarter results.
Patheon’s European HQ is up and running to help manage the firm’s growing European operations, specifically its development and commercial service offerings provided by units in France, Italy and the UK.
Patheon gave an update on its restructuring plans in Puerto Rico
yesterday, saying that its plant in Manati will be updated to
provide contract manufacturing of high-potency drugs and controlled
substances.
Patheon has finally revealed its plans to tackle the ongoing
problems it has been facing with its Puerto Rican operations, which
are draining the firm of profitability.
After dismal second quarter results Patheon is stepping up its
resolve for 'damage control' and indicated that further cutbacks at
its problematic Puerto Rico plant are imminent.
Canadian contract manufacturer Patheon has announced a $150m
(€114m) investment by a private equity firm - a move the company
sees as the best viable option to end its financial misery.
More problems at Patheon's Puerto Rican production facilities in
the third quarter of 2006 are expected to reduce the contract
manufacturer's earnings before interest, tax, depreciation and
amortisation (EBITDA) by more...
Canadian contract manufacturer Patheon saw pre-tax profits remain
idle in the second quarter of 2006, leaving it struggling to find
ways to boost profitability.
Canadian drug outsourcing company Patheon has reported its first
quarterly loss since its inception in 1974, swinging from a net
profit of $6m (€4.9m) in Q1 of 2005 to a net loss of $11.5m in Q1
of 2006, as problems with production...
Contract pharmaceutical manufacturer Patheon is to buy Puerto Rican
rival Mova Pharmaceuticals in a transaction that could be valued as
high as $350 million in cash, stock and assumed debt.
